Drugs in Development
All Data
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: UNIV TX MD ANDERSON
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 14, 2020
Details:
The alliance will combine MD Anderson’s clinical trials infrastructure and Sanofi’s pipeline of investigational treatments to lead biomarker-driven clinical studies to better understand how novel cancer drugs work.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 13, 2021
Details:
Taiho Pharmaceutical announces that it and Astex Pharmaceuticals, both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Boxer Capital
Deal Size: $162.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 07, 2021
Details:
Funds to support continued development of Scorpion’s drug hunting engine, which integrates unique capabilities across multiple fields of translational medicine, chemical biology, medicinal chemistry, and data science, as well as the advancement of Scorpion’s growing portfolio.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Next-generation T cell therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: Undisclosed Upfront Cash: $70.0 million
Deal Type: Collaboration January 07, 2021
Details:
ArsenalBio will deploy its full stack of synthetic biology compositions to build programmable cell therapy product candidates, composed of its PrimeR™ logic gates, CARchitecture™ derived gene expression controls, and CellFoundry™ mediated nonviral manufacturing.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
